MA43587A - Arnm thérapeutiques codant pour des anticorps anti-ctla-4 - Google Patents

Arnm thérapeutiques codant pour des anticorps anti-ctla-4

Info

Publication number
MA43587A
MA43587A MA043587A MA43587A MA43587A MA 43587 A MA43587 A MA 43587A MA 043587 A MA043587 A MA 043587A MA 43587 A MA43587 A MA 43587A MA 43587 A MA43587 A MA 43587A
Authority
MA
Morocco
Prior art keywords
ctla
antibodies
rna coding
therapeutic rna
therapeutic
Prior art date
Application number
MA043587A
Other languages
English (en)
Inventor
Joshua Frederick
Original Assignee
Modernatx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modernatx Inc filed Critical Modernatx Inc
Publication of MA43587A publication Critical patent/MA43587A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA043587A 2016-01-10 2017-01-10 Arnm thérapeutiques codant pour des anticorps anti-ctla-4 MA43587A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662276959P 2016-01-10 2016-01-10
US201662276958P 2016-01-10 2016-01-10
US201662290436P 2016-02-02 2016-02-02
US201662290435P 2016-02-02 2016-02-02

Publications (1)

Publication Number Publication Date
MA43587A true MA43587A (fr) 2018-11-14

Family

ID=57963448

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043587A MA43587A (fr) 2016-01-10 2017-01-10 Arnm thérapeutiques codant pour des anticorps anti-ctla-4

Country Status (4)

Country Link
US (1) US20190241658A1 (fr)
EP (1) EP3400023A1 (fr)
MA (1) MA43587A (fr)
WO (1) WO2017120612A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3077041T3 (fi) 2013-12-05 2024-10-16 Rfemb Holdings Llc Syövän immunoterapia radiotaajuisella sähköisellä solukalvon hajotuksella (rf-emb)
CA2975123A1 (fr) 2015-01-30 2016-08-04 Rfemb Holdings, Llc Rupture de membrane electrique par radiofrequence pour le traitement du cancer de la prostate a haut risque et recurrent, du cancer du pancreas impossible de resection, des tumeurs au sein, du melanome ou d'autres malignites de la peau, du sarcome, des tumeurs dans les tissus mous, du carcinome canalaire, de la neoplasie et des tissus anormaux intra- et....
DK3303394T3 (da) 2015-05-29 2020-07-06 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
CA3011460A1 (fr) 2016-01-15 2017-07-20 Rfemb Holdings, Llc Immunotherapie du cancer
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
IL307242B1 (en) 2016-12-07 2026-07-01 Agenus Inc Anti-CTLA-4 antibodies and methods of using them
RU2020115161A (ru) * 2017-10-06 2021-11-08 Дзе Уистар Инститьют Оф Энэтоми Энд Байолоджи Днк моноклональных антител против ctla-4 для лечения и профилактики рака
KR102834864B1 (ko) * 2018-02-02 2025-07-16 온코씨4, 아이앤씨. 개선된 면역치료 효과를 갖지만 약화된 부작용을 갖는 돌연변이 항-ctla-4 항체
EP3617230A1 (fr) * 2018-09-03 2020-03-04 BioInvent International AB Nouvelles séquences d'anticorps et de nucléotides et utilisations associées
MX2021005048A (es) 2018-10-31 2021-09-08 Bioatla Inc Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos.
US20220378700A1 (en) * 2019-10-18 2022-12-01 The Trustees Of The University Of Pennsylvania Lipid Nanoparticles and Formulations Thereof for CAR mRNA Delivery
KR102992305B1 (ko) * 2020-01-10 2026-07-21 주식회사 엘지화학 Mhc 및 종양 항원을 동시 발현하는 항원제시세포를 포함하는 조성물 및 이를 이용한 암 치료
KR20230042038A (ko) * 2020-07-27 2023-03-27 마크로제닉스, 인크. PD-1 x CTLA-4 이중특이적 분자의 사용 방법

Family Cites Families (201)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5563250A (en) 1987-12-02 1996-10-08 Neorx Corporation Cleavable conjugates for the delivery and release of agents in native form
US6140496A (en) 1990-10-09 2000-10-31 Benner; Steven Albert Precursors for deoxyribonucleotides containing non-standard nucleosides
US5505931A (en) 1993-03-04 1996-04-09 The Dow Chemical Company Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
US5681702A (en) 1994-08-30 1997-10-28 Chiron Corporation Reduction of nonspecific hybridization by using novel base-pairing schemes
US5585108A (en) 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6265389B1 (en) 1995-08-31 2001-07-24 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of oligonucleotides
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US20030073640A1 (en) 1997-07-23 2003-04-17 Ribozyme Pharmaceuticals, Inc. Novel compositions for the delivery of negatively charged molecules
US6426086B1 (en) 1998-02-03 2002-07-30 The Regents Of The University Of California pH-sensitive, serum-stable liposomes
WO1999054455A1 (fr) 1998-04-23 1999-10-28 Takara Shuzo Co., Ltd. Procede de synthese de l'adn
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
ES2706547T3 (es) 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
WO2000050006A2 (fr) 1999-02-26 2000-08-31 Chiron Corporation Microemulsions a macromolecules et microparticules adsorbees
EP1102785B1 (fr) 1999-06-07 2013-02-13 Arrowhead Research Corporation Compositions de diffusion de medicaments au moyen de molecules sensibles au ph
US7098032B2 (en) 2001-01-02 2006-08-29 Mirus Bio Corporation Compositions and methods for drug delivery using pH sensitive molecules
NZ517202A (en) * 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
AU2001233027A1 (en) 2000-01-27 2001-08-07 Genetics Institute, Llc Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
US6998115B2 (en) 2000-10-10 2006-02-14 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US6649138B2 (en) 2000-10-13 2003-11-18 Quantum Dot Corporation Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media
US7708915B2 (en) 2004-05-06 2010-05-04 Castor Trevor P Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein
US6897196B1 (en) 2001-02-07 2005-05-24 The Regents Of The University Of California pH sensitive lipids based on ortho ester linkers, composition and method
EP1412065A2 (fr) 2001-07-27 2004-04-28 President And Fellows Of Harvard College Appareil et procedes de melange de flux laminaires
CA2462593A1 (fr) 2001-10-03 2003-04-10 Kam W. Leong Compositions pour therapie genique orale et procedes d'utilisation associes
EP1452593B1 (fr) 2001-11-14 2009-04-08 Toyo Boseki Kabushiki Kaisha Promoteurs de replication de l'adn, facteurs associes a l'adn polymerase et utilisation de ces derniers
CA2409775C (fr) 2001-12-03 2010-07-13 F. Hoffmann-La Roche Ag Enzymes thermostables modifies de facon reversible pour la synthese de l'adn et l'amplification in vitro
US20050003014A1 (en) 2001-12-21 2005-01-06 Ketelson Howard Allen Use of synthetic inorganic nanoparticles as carriers for ophthalmic and otic drugs
US20050222064A1 (en) 2002-02-20 2005-10-06 Sirna Therapeutics, Inc. Polycationic compositions for cellular delivery of polynucleotides
JP4679822B2 (ja) 2002-03-13 2011-05-11 ノバルティス アーゲー 医薬微粒子
AU2003217531A1 (en) 2002-05-02 2003-11-17 Massachusetts Eye And Ear Infirmary Ocular drug delivery systems and use thereof
US7883720B2 (en) 2003-07-09 2011-02-08 Wisconsin Alumni Research Foundation Charge-dynamic polymers and delivery of anionic compounds
WO2005072710A2 (fr) 2004-01-28 2005-08-11 Johns Hopkins University Medicaments et particules de transport de genes se deplaçant rapidement a travers les barrieres muqueuses
CA2563533C (fr) 2004-04-15 2013-10-01 Shmuel A. Ben-Sasson Compositions capables de faciliter la penetration a travers une barriere biologique
US8178656B2 (en) 2004-06-11 2012-05-15 Trustees Of Tufts College Silk-based drug delivery system
WO2006063249A2 (fr) 2004-12-10 2006-06-15 Justin Hanes Copolymeres sequences de poly(ether-anhydride) fonctionnalises
US8192718B1 (en) 2005-01-04 2012-06-05 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
CA2597724A1 (fr) 2005-02-14 2007-08-02 Sirna Therapeutics, Inc. Compositions a base de nanoparticules lipidiques et methodes pour l'administration de molecules biologiquement actives
EP1865986B1 (fr) * 2005-03-08 2016-02-17 Pfizer Products Inc. Compositions d'anticorps anti-ctla-4
KR101288729B1 (ko) 2005-04-01 2013-07-23 인터자인 테크놀로지스, 인코포레이티드 약물 전달용 중합체성 마이셀
US8273339B2 (en) 2005-04-12 2012-09-25 Nektar Therapeutics Polymer-based compositions and conjugates of antimicrobial agents
US7550264B2 (en) 2005-06-10 2009-06-23 Datascope Investment Corporation Methods and kits for sense RNA synthesis
CA2611823C (fr) 2005-06-16 2013-07-30 Nektar Therapeutics Al, Corporation Conjugues a liaison degradable et reactifs polymeres utilises dans la preparation de ces conjugues
CA2611985C (fr) 2005-06-17 2016-08-16 The University Of North Carolina At Chapel Hill Procedes, systemes et materiaux de fabrication de nanoparticules
AU2006265896B2 (en) 2005-06-30 2012-05-31 Archemix Corp. Materials and methods for the generation of fully 2'-modified nucleic acid transcripts
US8101385B2 (en) 2005-06-30 2012-01-24 Archemix Corp. Materials and methods for the generation of transcripts comprising modified nucleotides
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
EP2319542B1 (fr) 2006-02-21 2018-03-21 Nektar Therapeutics Polymères dégradables segmentés et conjugués obtenus à partir de ceux-ci
CA2648291A1 (fr) 2006-04-04 2007-11-01 Stc.Unm Particules gonflantes pour l'administration d'un medicament
WO2007113648A2 (fr) 2006-04-05 2007-10-11 Pfizer Products Inc. Polythérapie à base d'un anticorps anti-ctla4
US8367113B2 (en) 2006-05-15 2013-02-05 Massachusetts Institute Of Technology Polymers for functional particles
JP2010502713A (ja) 2006-09-08 2010-01-28 ザ・ジョンズ・ホプキンス・ユニバーシティー 粘液を通る輸送を増強するための組成物および方法
US8313777B2 (en) 2006-10-05 2012-11-20 The Johns Hopkins University Water-dispersible oral, parenteral, and topical formulations for poorly water soluble drugs using smart polymeric nanoparticles
US20100210792A1 (en) 2006-12-05 2010-08-19 David Taft Drug delivery
US8399007B2 (en) 2006-12-05 2013-03-19 Landec Corporation Method for formulating a controlled-release pharmaceutical formulation
EP2120859B1 (fr) 2006-12-21 2013-11-20 Stryker Corporation Formulations à libération entretenue comprenant des cristaux de bmp-7
AU2007337810B2 (en) 2006-12-22 2014-02-13 Archemix Corp. Materials and methods for the generation of transcripts comprising modified nucleotides
WO2008092117A2 (fr) * 2007-01-25 2008-07-31 Xencor, Inc. Nouvelles insertions, délétions et substitutions d'immunoglobulines
WO2008103276A2 (fr) 2007-02-16 2008-08-28 Merck & Co., Inc. Compositions et méthodes de potentialisation de l'activité de molécules biologiquement actives
JP5249248B2 (ja) 2007-03-05 2013-07-31 ワシントン ユニバーシティー 膜組み込みペプチドのためのナノ粒子輸送システム
EP3434259A1 (fr) 2007-05-04 2019-01-30 Marina Biotech, Inc. Lipides d'acides aminés et utilisations associées
DK2205618T3 (en) 2007-09-26 2017-02-20 Intrexon Corp SYNTHETIC 5 'NON-TRANSLATED REGIONS, EXPRESSION VECTORS AND PROCEDURES FOR INCREASING TRANSGENIC EXPRESSION
ATE530169T1 (de) 2007-09-28 2011-11-15 Bind Biosciences Inc Krebszellen-targeting mit nanopartikeln
SG10201408164XA (en) 2007-12-11 2015-01-29 Scripps Research Inst Compositions and methods related to mrna translational enhancer elements
EP2279254B1 (fr) 2008-04-15 2017-07-05 Protiva Biotherapeutics Inc. Nouvelles formulations lipidiques pour l'administration d'acides nucléiques
JP5539962B2 (ja) 2008-04-25 2014-07-02 ノースウェスタン、ユニバーシティ コレステロールを隔離するのに適したナノ構造体
PL215513B1 (pl) 2008-06-06 2013-12-31 Univ Warszawski Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka
JP2011525180A (ja) 2008-06-16 2011-09-15 バインド バイオサイエンシズ インコーポレイテッド 治療的標的化ナノ粒子の製作に用いるためのジブロックコポリマーで官能化された標的薬の製造方法
AU2009268923B2 (en) 2008-06-16 2015-09-17 Pfizer Inc. Drug loaded polymeric nanoparticles and methods of making and using same
WO2010005726A2 (fr) 2008-06-16 2010-01-14 Bind Biosciences Inc. Nanoparticules polymères thérapeutiques avec inhibiteurs de mtor et procédés de fabrication et d’utilisation associés
EA020753B1 (ru) 2008-06-16 2015-01-30 Бинд Терапьютикс, Инк. Терапевтические полимерные наночастицы, содержащие алкалоиды vinca, и их применение
WO2010021865A1 (fr) 2008-08-18 2010-02-25 Merck Sharp & Dohme Corp. Nouvelles nanoparticules lipidiques et nouveaux composants pour l'administration d'acides nucléiques
WO2010030763A2 (fr) 2008-09-10 2010-03-18 Bind Biosciences, Inc. Fabrication de nanoparticles à rendement élevé
US20100075072A1 (en) 2008-09-25 2010-03-25 Tsung-Wei Chen Decorative structure of tree-shaped bells
WO2010053572A2 (fr) 2008-11-07 2010-05-14 Massachusetts Institute Of Technology Lipidoïdes aminoalcool et leurs utilisations
EA201100765A1 (ru) 2008-12-15 2012-04-30 Бинд Биосаиэнсис Наночастицы длительной циркуляции для замедленного высвобождения терапевтических средств
WO2010080724A1 (fr) 2009-01-12 2010-07-15 Merck Sharp & Dohme Corp. Nanoparticules lipidiques inédites et composants inédits utilisables pour l'administration d'acides nucléiques
WO2010087791A1 (fr) 2009-01-27 2010-08-05 Utc Power Corporation Réacteur de conversion à la vapeur d'eau intégré, refroidi de manière distributive et atomiseur
GB0903325D0 (en) 2009-02-26 2009-04-08 Univ Aberdeen Antibody molecules
JP5596712B2 (ja) 2009-03-12 2014-09-24 イリノイ トゥール ワークス インコーポレイティド 給油ミス防止装置
JP5622254B2 (ja) 2009-03-31 2014-11-12 国立大学法人東京大学 二本鎖リボ核酸ポリイオンコンプレックス
AU2010239689A1 (en) 2009-04-21 2011-11-03 Selecta Biosciences, Inc. Immunonanotherapeutics providing a Th1-biased response
WO2010127159A2 (fr) 2009-04-30 2010-11-04 Intezyne Technologies, Incorporated Micelles polymères pour l'encapsulation de polynucléotides
DE202009007116U1 (de) 2009-05-18 2010-10-14 Amoena Medizin-Orthopädie-Technik GmbH Antidekubituskissen
WO2010138193A2 (fr) 2009-05-27 2010-12-02 Selecta Biosciences, Inc. Nanosupports de synthèse ciblés se caractérisant par une libération sensible au ph d'agents immunomodulateurs
KR20220038506A (ko) 2009-06-10 2022-03-28 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
US8569256B2 (en) 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
ES2613498T3 (es) 2009-07-01 2017-05-24 Protiva Biotherapeutics Inc. Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos
US9181295B2 (en) 2009-08-20 2015-11-10 Sirna Therapeutics, Inc. Cationic lipids with various head groups for oligonucleotide delivery
US20120253032A1 (en) 2009-10-08 2012-10-04 Merck Sharp & Dohme Corporation Novel cationic lipids with short lipid chains for oligonucleotide delivery
RU2573409C2 (ru) 2009-11-04 2016-01-20 Дзе Юниверсити Оф Бритиш Коламбиа Содержащие нуклеиновые кислоты липидные частицы и относящиеся к ним способы
US8449916B1 (en) 2009-11-06 2013-05-28 Iowa State University Research Foundation, Inc. Antimicrobial compositions and methods
GB0920304D0 (en) 2009-11-20 2010-01-06 Medical Res Council Novel liposome nanoparticles for tumour magnetic resonance imaging
SI2506857T1 (en) 2009-12-01 2018-08-31 Translate Bio, Inc. Delivery of mRNA for the enrichment of proteins and enzymes in human genetic diseases
WO2011069529A1 (fr) 2009-12-09 2011-06-16 Curevac Gmbh Solution contenant du mannose pour la lyophilisation, la transfection et/ou l'injection d'acides nucléiques
CN102811743B (zh) 2009-12-11 2015-11-25 佰恩德治疗股份有限公司 冻干治疗颗粒的稳定制剂
EP2512487A4 (fr) 2009-12-15 2013-08-07 Nanoparticules polymères thérapeutiques comprenant de corticostéroïdes, et procédés pour les fabriquer et les utiliser
JP5965844B2 (ja) 2009-12-15 2016-08-10 バインド セラピューティックス インコーポレイテッド 高いガラス転移温度または高分子量のコポリマーを有する治療用ポリマーナノ粒子組成物
EP2512459A4 (fr) 2009-12-15 2013-08-07 Nanoparticules polymères thérapeutiques comportant de l'épothilone et leurs procédés de fabrication et d'utilisation
DE102009058769A1 (de) 2009-12-16 2011-06-22 MagForce Nanotechnologies AG, 10589 Temperaturabhängige Aktivierung von katalytischen Nukleinsäuren zur kontrollierten Wirkstofffreisetzung
WO2011076807A2 (fr) 2009-12-23 2011-06-30 Novartis Ag Lipides, compositions lipidiques, et procédés d'utilisation associés
US20130116419A1 (en) 2010-01-22 2013-05-09 Daniel Zewge Post-synthetic chemical modification of rna at the 2'-position of the ribose ring via "click" chemistry
EP2525815B1 (fr) 2010-01-24 2015-02-25 Novartis AG Microparticles polymériques biodégradables irradiées
US9149432B2 (en) 2010-03-19 2015-10-06 Massachusetts Institute Of Technology Lipid vesicle compositions and methods of use
US8207290B2 (en) 2010-03-26 2012-06-26 Cerulean Pharma Inc. Methods and systems for generating nanoparticles
EP3391877A1 (fr) 2010-04-08 2018-10-24 The Trustees of Princeton University Préparation de nanoparticules lipidiques
CN104922071A (zh) 2010-04-09 2015-09-23 帕西拉制药有限公司 用于配制大直径合成膜囊泡的方法
US20110262491A1 (en) 2010-04-12 2011-10-27 Selecta Biosciences, Inc. Emulsions and methods of making nanocarriers
WO2011139911A2 (fr) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Arn simple brin à formulation lipidique
WO2011143230A1 (fr) 2010-05-10 2011-11-17 Alnylam Pharmaceuticals Procédés et compositions pour la distribution d'agents actifs
US20130123338A1 (en) 2010-05-12 2013-05-16 Protiva Biotherapeutics, Inc. Novel cationic lipids and methods of use thereof
WO2011149733A2 (fr) 2010-05-24 2011-12-01 Merck Sharp & Dohme Corp. Nouveaux lipides cationiques alcools aminés pour l'administration d'oligonucléotides
WO2011147086A1 (fr) 2010-05-26 2011-12-01 江苏命码生物科技有限公司 Microvésicules contenant des petits arn interférents, leurs procédés de préparation et leurs utilisations
DK2575767T3 (en) 2010-06-04 2017-03-13 Sirna Therapeutics Inc HOWEVER UNKNOWN LOW MOLECULAR CATIONIC LIPIDS TO PROCESS OIGONUCLEOTIDES
BRPI1001959A2 (pt) 2010-06-15 2012-03-06 Instituto De Pesquisas Tecnológicas Do Est. S. Paulo S/a - Ipt Nanocarreadores coloidais para ativos hidrofílicos e processo de produção
US20130196948A1 (en) 2010-06-25 2013-08-01 Massachusetts Insitute Of Technology Polymers for biomaterials and therapeutics
FI4005592T3 (fi) 2010-07-06 2023-01-13 Virionin kaltaisia kuljetuspartikkeleita itsereplikoituville rna-molekyyleille
CA2804591C (fr) 2010-07-06 2019-01-22 Novartis Ag Emulsions cationiques huile-dans-eau
CN103153284B (zh) 2010-07-06 2015-11-25 诺华股份有限公司 含有其pKa值有利于RNA递送的脂质的脂质体
DE102010032758B4 (de) 2010-07-29 2012-02-23 Fujitsu Technology Solutions Intellectual Property Gmbh Computersystem, Verfahren zum Programmieren einer Echtzeituhr und Computerprogrammprodukt
EP2449113B8 (fr) 2010-07-30 2015-11-25 CureVac AG Complexation d'acides nucléiques avec des composants cationiques réticulés par des liaisons disulfure pour la transfection et l'immunostimulation
US9121065B2 (en) 2010-08-09 2015-09-01 The Trustees Of The University Of Pennsylvania Nanoparticle-oligonucleotide hybrid structures and methods of use thereof
US8956646B2 (en) 2010-08-14 2015-02-17 The Regents Of The University Of California Zwitterionic lipids
US20120225129A1 (en) 2010-08-20 2012-09-06 Cerulean Pharma Inc. Conjugates, particles, compositions, and related methods
EP3542789A3 (fr) 2010-08-31 2020-01-01 GlaxoSmithKline Biologicals SA Lipides adaptés pour une administration liposomale d'arn codant pour une protéine
RS63890B1 (sr) 2010-08-31 2023-02-28 Glaxosmithkline Biologicals Sa Mali lipozomi za isporuku rnk koja kodira imunogen
JP5911870B2 (ja) 2010-08-31 2016-04-27 ノバルティス アーゲー 免疫原をコードするｒｎａの送達のためのｐｅｇ化リポソーム
WO2012039979A2 (fr) 2010-09-10 2012-03-29 The Johns Hopkins University Diffusion rapide de grosses nanoparticules polymères dans le cerveau de mammifères
US8466122B2 (en) 2010-09-17 2013-06-18 Protiva Biotherapeutics, Inc. Trialkyl cationic lipids and methods of use thereof
ES2987915T3 (es) 2010-09-20 2024-11-18 Sirna Therapeutics Inc Nuevos lípidos catiónicos de bajo peso molecular para el suministro de oligonucleótidos
WO2012038448A1 (fr) 2010-09-21 2012-03-29 Riboxx Gmbh Procédé pour synthétiser de l'arn en utilisant une matrice d'adn
EP2621480B1 (fr) 2010-09-30 2018-08-15 Sirna Therapeutics, Inc. Lipides cationiques de faible masse moléculaire utilisables en vue de l'administration d'oligonucléotides
WO2012051220A1 (fr) 2010-10-11 2012-04-19 Wichita State University Système de délivrance de médicaments de nanoparticules magnétiques composites
WO2012054365A2 (fr) 2010-10-21 2012-04-26 Merck Sharp & Dohme Corp. Nouveaux lipides cationiques à faible poids moléculaire destinés à une administration d'oligonucléotides
EA201390600A1 (ru) 2010-10-22 2013-09-30 Байнд Терапьютикс, Инк. Терапевтические наночастицы с сополимерами с большим молекулярным весом
AU2011323250B2 (en) 2010-11-05 2015-11-19 The Johns Hopkins University Compositions and methods relating to reduced mucoadhesion
DK2635265T3 (en) 2010-11-05 2018-07-16 Sirna Therapeutics Inc New low molecular weight cyclic amine-containing cationic lipids for oligonucleotide delivery
US20120171229A1 (en) 2010-12-30 2012-07-05 Selecta Biosciences, Inc. Synthetic nanocarriers with reactive groups that release biologically active agents
US9999673B2 (en) 2011-01-11 2018-06-19 Alnylam Pharmaceuticals, Inc. PEGylated lipids and their use for drug delivery
WO2012099805A2 (fr) 2011-01-19 2012-07-26 Ocean Nanotech, Llc Stimulation immunologique à base de nanoparticules
US20140066363A1 (en) 2011-02-07 2014-03-06 Arun K. Bhunia Carbohydrate nanoparticles for prolonged efficacy of antimicrobial peptide
US8846850B2 (en) 2011-02-22 2014-09-30 Rutgers, The State University Of New Jersey Amphiphilic macromolecules for nucleic acid delivery
GB201103955D0 (en) 2011-03-09 2011-04-20 Antitope Ltd Antibodies
US20120244222A1 (en) 2011-03-25 2012-09-27 Selecta Biosciences, Inc. Osmotic mediated release synthetic nanocarriers
CA2831613A1 (fr) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Administration et formulation d'acides nucleiques genetiquement modifies
ES2820369T3 (es) 2011-03-31 2021-04-20 Ingell Tech Holding B V Composiciones biodegradables adecuadas para liberación controlada
EP2691078A1 (fr) 2011-03-31 2014-02-05 Ingell Technologies Holding B.V. Compositions biodégradables appropriées pour une libération contrôlée
US20120283503A1 (en) 2011-04-29 2012-11-08 The Johns Hopkins University Nanoparticle loaded stem cells and their use in mri guided hyperthermia
CN107320734A (zh) 2011-04-29 2017-11-07 西莱克塔生物科技公司 从合成纳米载体中控制释放免疫抑制剂
US8691750B2 (en) 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
US20140308363A1 (en) 2011-05-31 2014-10-16 Bind Therapeutics, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
CN107115314B (zh) 2011-06-02 2022-04-29 加利福尼亚大学董事会 膜包封的纳米颗粒及使用方法
KR20220025112A (ko) 2011-06-08 2022-03-03 샤이어 휴먼 지네틱 테라피즈 인크. Mrna 전달을 위한 지질 나노입자 조성물 및 방법
EP4074693A1 (fr) 2011-06-08 2022-10-19 Translate Bio, Inc. Lipides clivables
RU2014104090A (ru) 2011-07-06 2015-08-20 Новартис Аг Липосомы с эффективным соотношением n:p для доставки молекул phk
EP2734184B1 (fr) 2011-07-21 2018-03-28 Croda International Plc Copolymères à blocs de polyéther-polyamide ramifiés et leurs procédés de fabrication et d'utilisation
JP2014521687A (ja) 2011-07-29 2014-08-28 セレクタ バイオサイエンシーズ インコーポレーテッド 体液性および細胞傷害性ｔリンパ球（ｃｔｌ）免疫応答を生成する合成ナノキャリア
CA2842039A1 (fr) 2011-08-26 2013-03-07 Arrowhead Research Corporation Polymeres poly(ester vinyliques) pour administration d'acide nucleique in vivo
KR20140067070A (ko) 2011-08-31 2014-06-03 말린크로트 엘엘씨 Ｈ-포스포네이트에 의한 나노입자 ｐｅｇ 개질
US9126966B2 (en) 2011-08-31 2015-09-08 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use thereof
WO2013039857A1 (fr) 2011-09-12 2013-03-21 modeRNA Therapeutics Acides nucléiques modifiés et leurs procédés d'utilisation
WO2013044219A1 (fr) 2011-09-22 2013-03-28 Bind Biosciences Méthodes de traitement de cancers au moyen de nanoparticules thérapeutiques
US9375388B2 (en) 2011-09-23 2016-06-28 Indian Institute Of Technology, Bombay Nanoparticle based cosmetic composition
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
US20150272885A1 (en) 2011-10-14 2015-10-01 Stc.Unm Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof
AU2012325997C1 (en) 2011-10-18 2018-07-05 Dicerna Pharmaceuticals, Inc. Amine cationic lipids and uses thereof
US20140328759A1 (en) 2011-10-25 2014-11-06 The University Of British Columbia Limit size lipid nanoparticles and related methods
US9512073B2 (en) 2011-10-27 2016-12-06 Massachusetts Institute Of Technology Amino acid-, peptide-and polypeptide-lipids, isomers, compositions, and uses thereof
CN104023760A (zh) 2011-10-28 2014-09-03 普莱萨格生命科学公司 药物递送方法
CA2853689C (fr) 2011-11-04 2020-06-30 Nitto Denko Corporation Procede de fabrication de nanoparticules lipidiques pour une administration de medicament
AU2012340107B2 (en) 2011-11-18 2017-06-15 Regeneron Pharmaceuticals, Inc. Polymer protein microparticles
EP2785326A2 (fr) 2011-11-29 2014-10-08 The University of North Carolina at Chapel Hill Particules manipulées de façon géométrique et procédés de modulation de réponses des macrophages ou immunitaires
US9364549B2 (en) 2011-11-30 2016-06-14 Andreas Voigt Hydrophobic drug-delivery material, method for manufacturing thereof and methods for delivery of a drug-delivery composition
DE21212055T1 (de) 2011-12-07 2022-08-04 Alnylam Pharmaceuticals, Inc. Biologisch abbaubare lipide zur freisetzung von wirkstoffen
US20140308304A1 (en) 2011-12-07 2014-10-16 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
GB201121070D0 (en) 2011-12-07 2012-01-18 Isis Innovation composition for delivery of biotherapeutics
EP2787977A4 (fr) 2011-12-09 2015-05-06 Univ California Encapsulation liposomale de médicaments
CN109125286A (zh) 2011-12-13 2019-01-04 安吉尼科分子传输公司 用于将治疗剂递送至脑瘤的细菌衍生的、完整的微细胞
WO2013090601A2 (fr) 2011-12-16 2013-06-20 Massachusetts Institute Of Technology Nanoparticules compactes pour des applications biologiques
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
WO2013105101A1 (fr) 2012-01-13 2013-07-18 Department Of Biotechnology Nanoparticules lipidiques solides encapsulant un médicament hydrophile/amphiphile et leur procédé de préparation
US9415020B2 (en) 2012-01-19 2016-08-16 The Johns Hopkins University Nanoparticle formulations with enhanced mucosal penetration
WO2013116126A1 (fr) 2012-02-01 2013-08-08 Merck Sharp & Dohme Corp. Nouveaux lipides cationiques biodégradables de faible masse moléculaire pour la délivrance d'oligonucléotides
EP2809702B1 (fr) 2012-02-03 2017-12-20 Rutgers, The State University of New Jersey Biomatériaux polymères dérivés de monomères phénoliques et leurs utilisations à des fins médicales
US9737480B2 (en) 2012-02-06 2017-08-22 President And Fellows Of Harvard College ARRDC1-mediated microvesicles (ARMMs) and uses thereof
CN104245745B (zh) 2012-02-09 2017-03-29 生命技术公司 亲水性聚合物颗粒及其制备方法
WO2013120052A1 (fr) 2012-02-10 2013-08-15 E. I. Du Pont De Nemours And Company Préparation, purification et utilisation de copolymères à deux blocs à χ élevé
CN104394853B (zh) 2012-02-19 2017-10-10 纳维基因股份有限公司 多孔性纳米结构在递送中的用途
US9352042B2 (en) 2012-02-24 2016-05-31 Protiva Biotherapeutics, Inc. Trialkyl cationic lipids and methods of use thereof
WO2013151664A1 (fr) 2012-04-02 2013-10-10 modeRNA Therapeutics Polynucléotides modifiés pour la production de protéines
CN104411338A (zh) 2012-04-02 2015-03-11 现代治疗公司 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
US9512456B2 (en) 2012-08-14 2016-12-06 Modernatx, Inc. Enzymes and polymerases for the synthesis of RNA
WO2014093924A1 (fr) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Molécules d'acide nucléique modifiées et leurs utilisations
WO2014164253A1 (fr) 2013-03-09 2014-10-09 Moderna Therapeutics, Inc. Régions non traduites hétérologues pour arnm
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
WO2014209804A1 (fr) 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Anticorps bispécifiques
WO2015034925A1 (fr) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Polynucléotides circulaires
CA2923029A1 (fr) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Polynucleotides chimeriques
AU2014374055B2 (en) * 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof

Also Published As

Publication number Publication date
WO2017120612A1 (fr) 2017-07-13
US20190241658A1 (en) 2019-08-08
EP3400023A1 (fr) 2018-11-14

Similar Documents

Publication Publication Date Title
FR25C1001I2 (fr) Compositions d'anticorps pour le traitement de tumeurs
EP3347458A4 (fr) Cochon multi-transgénique pour xénogreffe
EP3386530A4 (fr) Peptides pour thérapie rénale
EP3630078A4 (fr) Agents pour chimio-embolisation
EP3423044A4 (fr) Nanovaccin activant sting pour l'immunothérapie
EP3387442A4 (fr) Anticorps anti-cd73 humanisés
EP3535588A4 (fr) Cibles thérapeutiques pour dystrophie musculaire facio-scapulo-humérale
EP3280421A4 (fr) Compositions pharmaceutiques pour thérapie combinée
MA40901A (fr) Anticorps bispécifiques anti-tnf/anti-il-3
FR3036518B1 (fr) Inversion pour contrainte tectonique
EP3383418A4 (fr) Peptides slc45a2 pour l'immunothérapie
MA51554A (fr) Anticorps il-6 améliorés
PL3687953T3 (pl) Opóźniacz do belitowego cementu wapniowo-siarczanoglinianowego
HUE046447T2 (hu) Betonfödém
IL260347A (en) Therapeutic anti-cd9 antibody
EP3383497A4 (fr) Nouveaux anticorps pour le traitement de cancers
EP3484517A4 (fr) Plate-forme modulaire pour thérapie ciblée
FR3042807B1 (fr) Autolestage pour banche de coffrage
EP3305350A4 (fr) Ensemble filtre-aiguille pour seringue
EP3347098A4 (fr) Ciblage de l'activation de mda-5 pour l'immunothérapie du cancer
EP3730141A4 (fr) Agent thérapeutique pour la pollakiurie nocturne
MA44378A (fr) Protéines de fusion immunogènes pour le traitement du cancer
EP2974728A4 (fr) Agents thérapeutiques pour un dysfonctionnement meibomien
EP3344287A4 (fr) Anticorps anti-survivine pour le traitement du cancer
EP3408731A4 (fr) Modes d'interaction pour interactions objet-dispositif